No Data
No Data
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $33
Weight-loss Drug Battle: Who Are the Latest Players Involved
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $15 to $40
Keros Therapeutics Is Maintained at Overweight by Wells Fargo
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns